Cenexi Q2 dip due to summer shutdown
Management acknowledged that Q2 FY26 will see lower EBITDA at Cenexi due to a one-month thermal shutdown, potentially delaying the turnaround trajectory.
medium · management_commentaryGland Pharma Limited — Q1 FY26
Gland Pharma reported a solid Q1 FY26 with consolidated revenue of INR 1,506 crore (+7% YoY) and EBITDA of INR 368 crore (+39% YoY), driving margins to 24% (up 500bps YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. tariff uncertainty on pharmaceuticals
An analyst raised concerns about potential U.S. tariffs under the Trump administration. Management noted no tariffs on pharma yet but acknowledged uncertainty and said they would pass on costs to partners.
medium · analyst_questionEnoxaparin revenue volatility
U.S. revenue was flat due to timing of Enoxaparin supplies, a large product. Management expects annual volumes to be intact but quarterly volatility may persist.
low · data_observationGLP-1 capacity utilization ramp-up slower than expected
Management indicated that the new 100 million cartridge line will not see significant utilization until FY29-30, as most markets open later. Near-term revenue contribution may be limited.
medium · management_commentary